Statin use and the risk of developing diabetes: a network meta‐analysis

  title={Statin use and the risk of developing diabetes: a network meta‐analysis},
  author={Divyesh Thakker and Sunita R. Nair and Amit Pagada and Vinayak Sudhir Jamdade and Anuradha Malik},
  journal={Pharmacoepidemiology and Drug Safety},
  pages={1131 - 1149}
Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta‐analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices. 
Statin users have an elevated risk of dysglycemia and new‐onset‐diabetes
This work sought to understand the risk of dysglycemia and NOD for a cohort of individuals that reflect real‐world physician prescribing patterns and identify patients at risk of new‐onset‐diabetes development.
Associations of statin use with glycaemic traits and incident type 2 diabetes
This study aimed to investigate the association of statin use with glycaemic traits and incident type 2 diabetes.
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
To evaluate the association of statins and co‐morbidities with new onset type 2 diabetes mellitus (T2DM) in patients 65 years and older, a large number of patients with T2DM are enrolled.
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.
Statins and diabetes: focus on pitavastatin
Particular attention is paid to the place of pitavastatin, due to its low diabetogenicity and minimal risk of drug interactions, as well as the need of taking into consideration the risk factors of diabetes and the preventive measures in patients receiving statin therapy.
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient.
  • J. Lillo
  • Medicine, Psychology
    The Journal of family practice
  • 2021
The nocebo effect is a common reason for perceived statin intolerance and several strategies are available that can enable continuation of statin therapy in patients who are truly statin-intolerant.
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
In this population at high risk for diabetes, the authors observed significantly higher rates of diabetes with statin therapy in all three treatment groups, and the effect of statins to increase diabetes risk appears to extend to populations at highrisk for diabetes.
Statin use and safety concerns: an overview of the past, present, and the future
The most common adverse effects of statins are described, available evidence is examined and the role of ethnicity, lipophilicity and other biological factors that could mediate and/or influence the relationship are highlighted.
Association between statin treatment and new-onset diabetes mellitus: a population based case–control study
The risk of NODM was not associated with an increase in the cumulative duration of statin use or with non-recent use, and only recent short-term use of cholesterol-lowering statin was associated with a increased risk ofNODM.
Diabetes Caused by Statin Use: A Review
Many studies have concluded that Pitavastatin and pravastatinom do not affect glycemic control and may be a beneficial treatment option in patients with, or at risk for, type 2 diabetes.


Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship ofstatin therapy to incident diabetes remains uncertain and future statin trials should be designed to formally address this issue.
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.
A meta-analysis and indirect comparisons employed to identify differing risk effects across statins found that atorvastatin significantly elevated AST levels compared to pravastatin and simvASTatin significantly increased CK levels when compared to rosuvastsatin.
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
Among people with impaired glucose tolerance and other cardiovascular risk factors and with serial glucose measurements, diuretics and statins were associated with an increased risk of new onset diabetes, whereas the effect of β blockers was non-significant.
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dosestatin therapy.
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
As a class, adverse events associated with statin therapy are not common but do result in a higher odds of diabetes mellitus and among individual statins, simvastatin and pravastatin seem safer and more tolerable than other statins.